Wednesday
Apr132016
NCT02754362
Determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose (Poly-ICLC) and bevacizumab in adults with recurrent glioblastoma.
Conditions: Glioblastoma, Glioma
Sponsor: New York University School of Medicine
Collaborator: Mount Sinai Hospital, New York
Phase 2